{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T07:16:41Z","timestamp":1791357401240,"version":"4.3.1"},"reference-count":47,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,6,13]],"date-time":"2017-06-13T00:00:00Z","timestamp":1497312000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","europeanneuropsychopharmacology.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Neuropsychopharmacology"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1016\/j.euroneuro.2017.05.009","type":"journal-article","created":{"date-parts":[[2017,6,27]],"date-time":"2017-06-27T05:31:53Z","timestamp":1498541513000},"page":"773-781","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"title":["Comparative evaluation of vortioxetine as a switch therapy in patients with major depressive disorder"],"prefix":"10.1016","volume":"27","author":[{"given":"Michael E.","family":"Thase","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalya","family":"Danchenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Brignone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioana","family":"Florea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francoise","family":"Diamand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula L.","family":"Jacobsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduard","family":"Vieta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euroneuro.2017.05.009_bib1","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1017\/S1461145711001027","article-title":"A double-blind, randomized, placebo-controlled, active reference study of Lu AA21004 in patients with major depressive disorder","volume":"15","author":"Alvarez","year":"2012","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2017.05.009_bib2","series-title":"Practice Guideline for the Treatment of Patients With Major Depressive Disorder","article-title":"Work Group on Major Depressive Disorder","author":"American Psychiatric Association (APA)","year":"2010"},{"key":"10.1016\/j.euroneuro.2017.05.009_bib3","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.curtheres.2005.04.006","article-title":"Antidepressant-related adverse effects impacting treatment compliance: results of a patient survey","volume":"66","author":"Ashton","year":"2005","journal-title":"Curr. Ther. Res. Clin. Exp."},{"key":"10.1016\/j.euroneuro.2017.05.009_bib4","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1177\/0269881116628440","article-title":"The safety and tolerability of vortioxetine: analysis of data from randomized placebo-controlled trials and open-label extension studies","volume":"30","author":"Baldwin","year":"2016","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2017.05.009_bib5","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.euroneuro.2011.11.008","article-title":"A randomised, double-blind, placebo controlled, duloxetine-referenced, fixed-dose study of three dosages of Lu AA21004 in acute treatment of major depressive disorder (MDD)","volume":"22","author":"Baldwin","year":"2012","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2017.05.009_bib47","doi-asserted-by":"crossref","unstructured":"Bang-Andersen, B., Ruhland, T., Jorgensen, M., Smith, G., Frederiksen, K., Jensen, K.G., Zhong, H., Nielsen, S.M., Hogg, S., Mork, A., Stensbol, T.B., 2011. Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder. J. Med. Chem. 54, 3206-3221","DOI":"10.1021\/jm101459g"},{"key":"10.1016\/j.euroneuro.2017.05.009_bib46","doi-asserted-by":"crossref","unstructured":"Bauer M. Pfennig A., Severus E., Whybrow P.C. Angst J. Moller H.J. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, part 1: update 2013 on the acute and continuation treatment of unipolar depressive disordersWorld J. Biol. Psychiatry 14, 2013, 334-385","DOI":"10.3109\/15622975.2013.804195"},{"key":"10.1016\/j.euroneuro.2017.05.009_bib7","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1097\/YIC.0000000000000018","article-title":"Efficacy and safety of vortioxetine (Lu AA21004), 15 and 20mg\/day: a randomized, double-blind, placebo-controlled, duloxetine-referenced study in the acute treatment of adult patients with major depressive disorder","volume":"29","author":"Boulenger","year":"2014","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2017.05.009_bib8","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1185\/03007995.2015.1128404","article-title":"Efficacy and tolerability of switching therapy to vortioxetine versus other antidepressants in patients with major depressive disorder","volume":"32","author":"Brignone","year":"2016","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.euroneuro.2017.05.009_bib9","article-title":"Switching the antidepressant after nonresponse in adults with major depression: a systematic literature search and meta-analysis","author":"Bschor","year":"2016","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2017.05.009_bib10","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/S0895-4356(97)00049-8","article-title":"The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials","volume":"50","author":"Bucher","year":"1997","journal-title":"J. Clin. Epidemiol."},{"key":"10.1016\/j.euroneuro.2017.05.009_bib11","unstructured":"European Medicines Agency, 2000. European Medicines Agency (EMEA). Committee for Medicinal Products for Human Use (CHMP). Points to consider on switching between superiority and non-inferiority. \u3008http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2009\/09\/WC500003658.pdf\u3009. (Accessed 17 June 2016)."},{"key":"10.1016\/j.euroneuro.2017.05.009_bib12","unstructured":"Forest Pharmaceuticals Inc., 2014. Lexapro [package insert], St. Louis, MO."},{"key":"10.1016\/j.euroneuro.2017.05.009_bib13","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1186\/1471-244X-12-143","article-title":"Treatment patterns in major depressive disorder after an inadequate response to first-line antidepressant treatment","volume":"12","author":"Garcia-Toro","year":"2012","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.euroneuro.2017.05.009_bib14","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1097\/JCP.0b013e31823f705d","article-title":"Treating depression after initial treatment failure: directly comparing switch and augmenting strategies in STAR*D","volume":"32","author":"Gaynes","year":"2012","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2017.05.009_bib15","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1002\/da.22378","article-title":"The American Society of Clinical Psychopharmacology survey of psychopharmacologists\u05f3 practice patterns for the treatment of mood disorders","volume":"32","author":"Goldberg","year":"2015","journal-title":"Depress. Anxiety"},{"key":"10.1016\/j.euroneuro.2017.05.009_bib16","doi-asserted-by":"crossref","DOI":"10.1111\/bph.12720","article-title":"Agomelatine: mechanism of action and pharmacological profile in relation to antidepressant properties","author":"Guardiola-Lemaitre","year":"2014","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.euroneuro.2017.05.009_bib17","series-title":"ECDEU Assessment Manual for Psychopharmacology","article-title":"Clinical Global Impressions (028-CGI)","author":"Guy","year":"1976"},{"key":"10.1016\/j.euroneuro.2017.05.009_bib18","doi-asserted-by":"crossref","first-page":"953","DOI":"10.4088\/JCP.11m07470","article-title":"A randomized, double-blind, placebo-controlled 8-week trial of the efficacy and tolerability of multiple doses of Lu AA21004 in adults with major depressive disorder","volume":"73","author":"Henigsberg","year":"2012","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2017.05.009_bib19","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1111\/jsm.12980","article-title":"Effect of vortioxetine vs. escitalopram on sexual functioning in adults with well-treated major depressive disorder experiencing SSRI-Induced sexual dysfunction","volume":"12","author":"Jacobsen","year":"2015","journal-title":"J. Sex. Med."},{"key":"10.1016\/j.euroneuro.2017.05.009_bib20","doi-asserted-by":"crossref","first-page":"575","DOI":"10.4088\/JCP.14m09335","article-title":"A randomized, double-blind, placebo-controlled study of the efficacy and safety of vortioxetine 10mg and 20mg in adults with major depressive disorder","volume":"76","author":"Jacobsen","year":"2015","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2017.05.009_bib21","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1017\/S1461145712000727","article-title":"A randomized, double-blind, placebo-controlled 6-wk trial of the efficacy and tolerability of 5mg vortioxetine in adults with major depressive disorder","volume":"16","author":"Jain","year":"2013","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2017.05.009_bib22","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/j.euroneuro.2013.05.010","article-title":"The efficacy of agomelatine in previously-treated depressed patients","volume":"23","author":"Kasper","year":"2013","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2017.05.009_bib23","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1097\/YIC.0b013e3283542457","article-title":"A randomized, double-blind, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder","volume":"27","author":"Katona","year":"2012","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2017.05.009_bib24","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1080\/00926230500232909","article-title":"Reliability and construct validity of the Changes in Sexual Functioning Questionnaire short-form (CSFQ-14)","volume":"32","author":"Keller","year":"2006","journal-title":"J. Sex Marital Ther."},{"key":"10.1016\/j.euroneuro.2017.05.009_bib25","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1185\/03007995.2015.1020362","article-title":"Pharmacotherapeutic strategies for patients treated for depression in UK primary care: a database analysis","volume":"31","author":"Lamy","year":"2015","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.euroneuro.2017.05.009_bib26","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1097\/YIC.0b013e3282f424c2","article-title":"Venlafaxine extended release versus citalopram in patients with depression unresponsive to a selective serotonin reuptake inhibitor","volume":"23","author":"Lenox-Smith","year":"2008","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2017.05.009_bib27","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1007\/s00213-014-3839-0","article-title":"A randomized, double-blind, duloxetine-referenced study comparing efficacy and tolerability of 2 fixed doses of vortioxetine in the acute treatment of adults with MDD","volume":"232","author":"Mahableshwarkar","year":"2015","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.euroneuro.2017.05.009_bib28","doi-asserted-by":"crossref","first-page":"583","DOI":"10.4088\/JCP.14m09337","article-title":"A randomized, double-blind, placebo-controlled study of the efficacy and safety of 2 doses of vortioxetine in adults with major depressive disorder","volume":"76","author":"Mahableshwarkar","year":"2015","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2017.05.009_bib29","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1185\/03007995.2012.761600","article-title":"A randomized, double-blind trial of 2.5mg and 5mg vortioxetine (Lu AA21004) versus placebo for 8 weeks in adults with major depressive disorder","volume":"29","author":"Mahableshwarkar","year":"2013","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.euroneuro.2017.05.009_bib30","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1016\/S0149-2918(03)80220-5","article-title":"Tolerability and adherence issues in antidepressant therapy","volume":"25","author":"Masand","year":"2003","journal-title":"Clin. Ther."},{"key":"10.1016\/j.euroneuro.2017.05.009_bib31","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1017\/S1461145714000546","article-title":"A randomized, double-blind, placebo-controlled study of vortioxetine on cognitive function in depressed adults","volume":"17","author":"McIntyre","year":"2014","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2017.05.009_bib32","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1002\/hup.2424","volume":"29","author":"Montgomery","year":"2014","journal-title":"Hum. Psychopharmacol. Clin. Exp."},{"key":"10.1016\/j.euroneuro.2017.05.009_bib33","series-title":"Depression: The Treatment and Management of Depression in Adults (Updated Edition)","author":"National Collaborating Centre for Mental Health (NCCMH)","year":"2010"},{"key":"10.1016\/j.euroneuro.2017.05.009_bib34","unstructured":"Nishimura, A., Hirochi, K., Asari, K., Otake, K., Mahableshwarkar, A.R., 2014. 06. A multinational, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of vortioxetine 5, 10, and 20mg in adults with major depressive disorder [abstract], 27th Annual US Psychiatric and Mental Health Congress, Orlando, FL."},{"key":"10.1016\/j.euroneuro.2017.05.009_bib35","unstructured":"Papakostas, G., Dragheim, M., Nielsen, R.Z., 2014a. NR6-118 Efficacy and tolerability of vortioxetine vs agomelatine is independent of previous treatment in MDD patients switched after an inadequate response [abstract], 167th Annual Meeting of the American Psychiatric Association, New York, NY."},{"issue":"Supplement 2","key":"10.1016\/j.euroneuro.2017.05.009_bib36","doi-asserted-by":"crossref","first-page":"S466","DOI":"10.1016\/S0924-977X(14)70745-X","article-title":"P.2.f.024 Efficacy and tolerability of vortioxetine is independent of previous treatment in MDD patients switched after an inadequate response","volume":"24","author":"Papakostas","year":"2014","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2017.05.009_bib37","doi-asserted-by":"crossref","first-page":"603","DOI":"10.2147\/PPA.S42789","article-title":"Efficacy and tolerability of agomelatine in the treatment of depression","volume":"8","author":"Plesnicar","year":"2014","journal-title":"Patient Prefer. Adherence"},{"key":"10.1016\/j.euroneuro.2017.05.009_bib38","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1176\/ajp.2006.163.11.1905","article-title":"Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report","volume":"163","author":"Rush","year":"2006","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2017.05.009_bib39","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1056\/NEJMoa052963","article-title":"Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression","volume":"354","author":"Rush","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.euroneuro.2017.05.009_bib48","doi-asserted-by":"crossref","unstructured":"Sanchez, C., Asin, K.E., Artigas, F., 2015. Vortioxetine, a novel antidepressant with multimodal activity: review of preclinical and clinical data. Pharmacol. Ther. 145, 43-57.","DOI":"10.1016\/j.pharmthera.2014.07.001"},{"key":"10.1016\/j.euroneuro.2017.05.009_bib40","first-page":"41","article-title":"Antidepressant adherence: are patients taking their medications?","volume":"9","author":"Sansone","year":"2012","journal-title":"Innov. Clin. Neurosci."},{"key":"10.1016\/j.euroneuro.2017.05.009_bib41","unstructured":"Santaguida, P., MacQueen, G., Keshavarz, H., Levine, M., Beyene, J., Raina, P., 2012.\u00a0Treatment for Depression After Unsatisfactory Response to SSRIs. Comparative Effectiveness Review No. 62. (Prepared by McMaster University Evidence-based Practice Center under Contract No. HHSA 290 2007 10060 I.) AHRQ Publication No.12-EHC050-EF. Rockville, MD: Agency for Healthcare Research and Quality, April 2012."},{"key":"10.1016\/j.euroneuro.2017.05.009_bib42","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1097\/JCP.0b013e3181a5233f","article-title":"Treatment-emergent sexual dysfunction related to antidepressants: a meta-analysis","volume":"29","author":"Serretti","year":"2009","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2017.05.009_bib43","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1017\/S1092852914000248","article-title":"Mechanism of action of agomelatine: a novel antidepressant exploiting synergy between monoaminergic and melatonergic properties","volume":"19","author":"Stahl","year":"2014","journal-title":"CNS Spectr."},{"key":"10.1016\/j.euroneuro.2017.05.009_bib44","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.euroneuro.2016.02.003","article-title":"Randomized controlled study of early medication change for non-improvers to antidepressant therapy in major depression - The EMC trial","volume":"26","author":"Tadic","year":"2016","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2017.05.009_bib45","unstructured":"Westrich, L., Pehrson, A., Zhong, H., Nielsen, S.M., Frederiksen, K., Stensbol, T.B., Boyle, N.J., Hentzer, M., Sanchez, C., 2012. In vitro and in vivo effects for the multimodal antidepressant vortioxetine (Lu AA21004) at human and rat targets. Int. J. Psychiatry Clin. Pract. 16, 47."}],"container-title":["European Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X17302547?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X17302547?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,31]],"date-time":"2018-08-31T06:23:52Z","timestamp":1535696632000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924977X17302547"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8]]},"references-count":47,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2017,8]]}},"alternative-id":["S0924977X17302547"],"URL":"https:\/\/doi.org\/10.1016\/j.euroneuro.2017.05.009","relation":{},"ISSN":["0924-977X"],"issn-type":[{"value":"0924-977X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative evaluation of vortioxetine as a switch therapy in patients with major depressive disorder","name":"articletitle","label":"Article Title"},{"value":"European Neuropsychopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euroneuro.2017.05.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}